[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647949":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":55,"collaborators":26,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":26,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":65,"minAge":66,"maxAge":26,"enrollmentInfo":67,"targetDuration":26,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Rambam Health Care Campus","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Calcium Gluconate","EXPERIMENTAL","Participants will receive 10 mL of 10% calcium gluconate solution (0.94 g calcium gluconate) diluted in 100 mL normal saline administered intravenously immediately following umbilical cord clamping during the third stage of labor.",[13],"Drug: calcium gluconate",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo (Normal Saline)","PLACEBO_COMPARATOR","Participants will receive 110 mL of 0.9% normal saline administered intravenously immediately following umbilical cord clamping during the third stage of labor.",[19],"Drug: Normal saline placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","calcium gluconate","10 mL of 10% calcium gluconate solution (0.94 g calcium gluconate) diluted in 100 mL of normal saline and administered intravenously immediately following umbilical cord clamping during the third stage of labor.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Normal saline placebo","110 mL of 0.9% normal saline administered intravenously immediately following umbilical cord clamping during the third stage of labor",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Gili Buchnik Fater, MD","CONTACT","+972546738628","gili.buchnik@gmail.com",[38],{"facility":39,"status":40,"city":41,"state":26,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Rambam Medical Center","RECRUITING","Haifa","6815408","Israel","IL",{"type":46,"coordinates":47},"Point",[48,49],34.99928,32.81303,{"lat":49,"lon":48},[52,53],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"name":33,"role":54,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"type":56,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100647949","administration-of-calcium-gluconate-for-the-reduction-of-blood-loss-during-vaginal-delivery-100647949",false,"NCT07714902","Administration Of Calcium Gluconate for The Reduction of Blood Loss During Vaginal Delivery","Administration of Calcium Gluconate for the Reduction of Blood Loss During Vaginal Delivery: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Gestational age of 37 weeks or more, and planning a vaginal delivery.\n\nExclusion Criteria:\n\n* Age younger than 18 years old.\n* Patients treated with calcium channel blockers\n* Patients with Preeclampsia with severe features receiving magnesium sulfate infusion.\n* Chronic renal failure and hyperphosphatemia\n* Patients with known Para-Thyroid disease\n* Sarcoidosis",true,"MALE","18 Years",{"count":68,"type":69},710,"ESTIMATED","INTERVENTIONAL",[72],"NA","Postpartum hemorrhage is one of the leading causes of maternal morbidity following childbirth. Even when excessive bleeding is not clinically recognized, some women experience a significant decrease in hemoglobin levels after delivery, which may result in anemia, fatigue, delayed recovery, and the need for additional medical treatment.\n\nCalcium plays an important role in uterine muscle contraction and blood clotting. Previous studies have suggested that calcium administration may help reduce blood loss after childbirth. However, there is limited evidence regarding its effectiveness during vaginal delivery.\n\nThe purpose of this study is to evaluate whether administration of intravenous calcium gluconate immediately after umbilical cord clamping can reduce postpartum blood loss following vaginal delivery.\n\nParticipants will be randomly assigned to receive either calcium gluconate or a placebo solution immediately after umbilical cord clamping during vaginal delivery. Neither the participants nor their healthcare providers will know which treatment was administered. Blood tests routinely obtained during hospitalization after delivery will be used to assess changes in hemoglobin levels and other outcomes related to postpartum bleeding.\n\nThe results of this study may help determine whether calcium gluconate is a safe and effective intervention for reducing postpartum blood loss after vaginal delivery.",[75],"Postpartum Hemorrhage",[75,77,9,78,79,80],"Postpartum Blood Loss","Vaginal Delivery","Uterine Atony","Third Stage of Labor","2026-07-14",{"date":83,"type":84},"2026-07-20","ACTUAL",{"date":86,"type":69},"2026-06-24",{"date":88,"type":69},"2027-12-01",{"name":5,"class":6},1]